Effect of Pokeweed antiviral protein on hepatitis C virus IRES
美洲商陆抗病毒蛋白对丙型肝炎病毒IRES的影响
基本信息
- 批准号:7034327
- 负责人:
- 金额:$ 7.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-01-15 至 2007-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): We propose to test the effect of pokeweed antiviral protein (PAP) on translation mediated by the internal ribosome entry sites (IRES) of hepatitis C virus (HCV). HCV is the major cause of chronic hepatitis which can result in life threatening cirrhosis and hepatocellular carcinoma. A global survey by WHO in 1999 estimated that at least 170 million people in the world are chronically infected with HCV. Presently interferon is the best treatment for chronic hepatitis. However, it is associated with relatively poor efficacy and unfavorable side effects. PAP is a 29-kDa antiviral/antifungal protein isolated from Phytolacca americana. It belongs to a group of proteins called the ribosome inactivating proteins (RIPs). RIPs are known to catalytically remove a specific adenine residue from the highly conserved alpha-sarcin/ricin loop (SRL) in the large rRNA of eukaryotic and prokaryotic ribosomes, a process called depurination. Our study has indicated that in addition to the previously identified adenine (A4324), PAP removes another adenine (A4321) and a guanine (G4323) from the eukaryotic large rRNA resulting in inhibition of translation. HCV RNA translation is mediated by a complex RNA element called the internal ribosome entry site (IRES), located within the 5' untranslated region of the viral RNA. The current structural model of HCV IRES indicates the presence of four major stem-loops I-IV and a pseudoknot. Except for stem-loop I, all are required for translation initiation. Two SRL motifs have been found on stem-loops II and Illd. Our preliminary studies have indicated that PAP can affect the HCV IRES and reduce the reporter firefly luciferase activity significantly. In addition, a non- toxic PAP mutant can inhibit the translation mediated by HCV IRES as efficiently as wild type PAP. PAP may exert its detrimental effect through depurination, possibly on the SRL motifs found on the HCV IRES element. Therefore, specific aims of this application are to: (1) determine if nontoxic PAP mutants inhibit HCV IRES directed translation and whether they destabilize the reporter mRNA, (2) determine if PAP inhibits HCV IRES-mediated translation by binding to the HCV IRES and depurinating the SRL motifs, (3) identify the PAP binding and depurination sites on the HCV IRES and determine if these sequences arp critical for inhibition on IRES-mediated translation. This study will lay the groundwork for designing novel drugs against HCV for the treatment of chronic hepatitis.
描述(由申请人提供):我们建议测试美洲商陆抗病毒蛋白(PAP)对丙型肝炎病毒(HCV)内部核糖体进入位点(IRES)介导的翻译的影响。HCV是慢性肝炎的主要病因,慢性肝炎可导致危及生命的肝硬化和肝细胞癌。世卫组织1999年的一项全球调查估计,世界上至少有1.7亿人慢性感染HCV。干扰素是目前治疗慢性肝炎的最佳药物。然而,它与相对较差的疗效和不利的副作用有关。PAP是从美洲商陆中分离的29-kDa抗病毒/抗真菌蛋白。它属于一组称为核糖体失活蛋白(RIP)的蛋白质。已知RIPs可催化去除真核和原核核糖体大rRNA中高度保守的α-八叠球菌素/蓖麻毒素环(SRL)中的特定腺嘌呤残基,该过程称为脱嘌呤。我们的研究表明,除了先前确定的腺嘌呤(A4324),PAP删除另一个腺嘌呤(A4321)和鸟嘌呤(G4323)从真核生物大rRNA导致抑制翻译。HCV RNA的翻译是由一个复杂的RNA元件介导的,称为内部核糖体进入位点(IRES),位于病毒RNA的5'非翻译区。目前的HCV IRES结构模型表明存在四个主要的茎环I-IV和一个假结。除茎环I外,其他都是翻译起始所必需的。在茎环II和IIId上发现了两个SRL基序。我们的初步研究表明,PAP可以影响HCV IRES,并显着降低报告萤火虫荧光素酶活性。此外,无毒PAP突变体可以与野生型PAP一样有效地抑制HCV IRES介导的翻译。PAP可能通过脱嘌呤作用对HCV IRES元件上发现的SRL基序发挥其有害作用。因此,本申请的具体目的是:(1)确定无毒PAP突变体是否抑制HCV IRES指导的翻译以及它们是否使报告mRNA不稳定,(2)确定PAP是否通过结合HCV IRES并使SRL基序脱嘌呤而抑制HCV IRES介导的翻译,(3)鉴定HCV IRES上的PAP结合和脱嘌呤位点,并确定这些序列阿普是否对抑制IRES介导的翻译至关重要。本研究为设计新型抗HCV药物治疗慢性肝炎奠定了基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RONG DI其他文献
RONG DI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RONG DI', 18)}}的其他基金
Effect of Pokeweed antiviral protein on hepatitis C virus IRES
美洲商陆抗病毒蛋白对丙型肝炎病毒IRES的影响
- 批准号:
7168810 - 财政年份:2006
- 资助金额:
$ 7.7万 - 项目类别:
相似海外基金
CD38 modulation of NAD metabolism driving scleroderma pathogenesis
CD38 调节 NAD 代谢驱动硬皮病发病机制
- 批准号:
10733929 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别:
Soft wireless multimodal cardiac implantable devices for long-term investigating heart failure pathogenesis
用于长期研究心力衰竭发病机制的软无线多模式心脏植入装置
- 批准号:
10735395 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别:
Red blood cell ATP export and transfusion in sepsis
脓毒症中红细胞 ATP 输出和输血
- 批准号:
10584768 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别:
Preservation of brain NAD+ as a novel non-amyloid based therapeutic strategy for Alzheimer’s disease
保留大脑 NAD 作为阿尔茨海默病的一种新型非淀粉样蛋白治疗策略
- 批准号:
10588414 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别:
Unravelling highly pathogenic influenza virus emergence
揭开高致病性流感病毒出现的谜团
- 批准号:
10718091 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别:
Role of Sarm1 in TBI-accentuated C9orf72 Frontotemporal Dementia
Sarm1 在 TBI 加重的 C9orf72 额颞叶痴呆中的作用
- 批准号:
10646932 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别:
Novel Combinations of Natural Product Compounds for Treatment of Alzheimer Disease and Related Dementias
用于治疗阿尔茨海默病和相关痴呆症的天然产物化合物的新组合
- 批准号:
10603708 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别:
A novel therapeutic approach for Alzheimer Disease (AD)
阿尔茨海默病(AD)的新治疗方法
- 批准号:
10740016 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别:
Targeting DNA Mismatches for Auger Electron Radiotherapy
针对 DNA 错配进行俄歇电子放射治疗
- 批准号:
10751210 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别:
Anti-Aging Molecule Sirt6 in Neuroprotection in Diabetic Retina
抗衰老分子 Sirt6 对糖尿病视网膜神经保护作用
- 批准号:
10568150 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别: